Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Phio Pharmaceuticals (NASDAQ: PHIO) announced a presentation at the 9th Annual CAR-TCR Summit in Boston, MA, showcasing its INTASYL self-delivering RNAi technology. The presentation, titled 'INTASYL Self-Delivering RNAi: A Flexible Platform to Improve Adoptive Cell Therapy,' will be given by Melissa Maxwell on September 17th. INTASYL is designed to enhance cell potency and yield in Adoptive Cell Therapy, potentially offering a more effective approach for cancer treatment. The technology aims to make immune cells more effective in killing tumor cells through gene silencing. This presentation highlights Phio's efforts to advance its innovative platform in the competitive field of cell therapy.
Phio Pharmaceuticals (NASDAQ: PHIO) ha annunciato una presentazione al 9° Annual CAR-TCR Summit a Boston, MA, in cui metterà in mostra la sua tecnologia RNAi autoconsegnante INTASYL. La presentazione, intitolata 'INTASYL RNAi Autoconsegna: Una Piattaforma Flessibile per Migliorare la Terapia Cellulare Adottiva,' sarà tenuta da Melissa Maxwell il 17 settembre. INTASYL è progettata per migliorare la potenza e il rendimento cellulare nella Terapia Cellulare Adottiva, offrendo potenzialmente un approccio più efficace per il trattamento del cancro. La tecnologia mira a rendere le cellule immunitarie più efficaci nell'uccidere le cellule tumorali attraverso il silenziamento genico. Questa presentazione evidenzia gli sforzi di Phio per far avanzare la sua piattaforma innovativa nel competitivo campo della terapia cellulare.
Phio Pharmaceuticals (NASDAQ: PHIO) anunció una presentación en el 9° Annual CAR-TCR Summit en Boston, MA, donde exhibirá su tecnología RNAi autoconducente INTASYL. La presentación, titulada 'INTASYL RNAi Autoconducente: Una Plataforma Flexible para Mejorar la Terapia Celular Adoptiva,' será presentada por Melissa Maxwell el 17 de septiembre. INTASYL está diseñada para mejorar la potencia y el rendimiento celular en la Terapia Celular Adoptiva, ofreciendo potencialmente un enfoque más efectivo para el tratamiento del cáncer. La tecnología busca hacer que las células inmunitarias sean más eficaces en la eliminación de células tumorales a través del silenciamiento de genes. Esta presentación destaca los esfuerzos de Phio por avanzar en su plataforma innovadora en el competitivo campo de la terapia celular.
Phio Pharmaceuticals (NASDAQ: PHIO)는 매사추세츠주 보스턴에서 열리는 제9회 CAR-TCR 서밋에서 자사 INTASYL 자가전달 RNAi 기술을 선보일 것이라고 발표했습니다. 'INTASYL 자가전달 RNAi: 세포 치료를 개선하기 위한 유연한 플랫폼'이라는 제목의 발표는 9월 17일 Melissa Maxwell에 의해 진행될 예정입니다. INTASYL은 세포 치료에서 세포의 효능과 수율을 향상시키기 위해 설계되었으며, 암 치료에 대해 더 효과적인 접근 방식을 제공할 가능성이 있습니다. 이 기술은 유전자 침묵을 통해 면역 세포가 종양 세포를 더 효과적으로 제거할 수 있도록 하는 것을 목표로 합니다. 이 발표는 세포 치료의 경쟁 분야에서 Phio의 혁신적인 플랫폼을 발전시키기 위한 노력을 강조합니다.
Phio Pharmaceuticals (NASDAQ: PHIO) a annoncé une présentation lors du 9ème Sommet annuel CAR-TCR à Boston, MA, où elle mettra en avant sa technologie RNAi autodélivrée INTASYL. La présentation, intitulée 'INTASYL RNAi Autodélivrance : Une plateforme flexible pour améliorer la thérapie cellulaire adoptive,' sera donnée par Melissa Maxwell le 17 septembre. INTASYL est conçue pour améliorer la puissance et le rendement cellulaire dans la thérapie cellulaire adoptive, offrant ainsi potentiellement une approche plus efficace pour le traitement du cancer. La technologie vise à rendre les cellules immunitaires plus efficaces pour tuer les cellules tumorales grâce à un silençage génique. Cette présentation met en lumière les efforts de Phio pour faire progresser sa plateforme innovante dans le domaine concurrentiel de la thérapie cellulaire.
Phio Pharmaceuticals (NASDAQ: PHIO) hat eine Präsentation beim 9. jährlichen CAR-TCR-Gipfel in Boston, MA, angekündigt, bei der die INTASYL selbstliefernde RNAi-Technologie vorgestellt wird. Die Präsentation mit dem Titel 'INTASYL Selbstliefernde RNAi: Eine flexible Plattform zur Verbesserung der adoptiven Zelltherapie' wird am 17. September von Melissa Maxwell gehalten. INTASYL ist darauf ausgelegt, die Zellleistung und -ausbeute bei der adoptiven Zelltherapie zu verbessern und möglicherweise einen effektiveren Ansatz zur Behandlung von Krebs anzubieten. Die Technologie zielt darauf ab, Immunzellen durch Gen-Silencing effektiver im Abtöten von Tumorzellen zu machen. Diese Präsentation hebt die Bemühungen von Phio hervor, ihre innovative Plattform im wettbewerbsintensiven Bereich der Zelltherapie voranzubringen.
- Presenting at a major industry event (CAR-TCR Summit) increases visibility
- INTASYL technology potentially enhances cell potency and yield in cancer treatment
- Platform offers flexibility in improving adoptive cell therapy
- None.
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy
Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its INTASYL technology platform which represents an innovative and flexible solution for adoptive cell therapy providing compounds designed specifically to enhance cell potency and improve overall yield, offering a more effective approach for treating cancer.
The data will be presented at the CAR-TCR Summit taking place September 17-20 in Boston, MA.
Presentation Details are as follows:
| Title: | INTASYL Self-Delivering RNAi: A Flexible Platform to Improve Adoptive Cell Therapy |
| Presenting Author: | Melissa Maxwell |
| Date and Time: | Tuesday, September 17th from 6:00 -7:30 pm |
| Location: | Hynes Convention Center, 900 Boylston St, Boston, MA |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary technology, INTASYL, precisely silences virtually any gene in the human genome. In addition to targeting solid tumors, INTASYL can effectively enhance applications in adoptive cell therapy.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs, Phio Pharmaceuticals Corp.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222999
FAQ
What is Phio Pharmaceuticals presenting at the 9th Annual CAR-TCR Summit?
When and where is Phio Pharmaceuticals' presentation at the CAR-TCR Summit?
What is the potential benefit of Phio Pharmaceuticals' INTASYL technology for cancer treatment?
Who is presenting Phio Pharmaceuticals' INTASYL technology at the CAR-TCR Summit?
